|
000
| 01327cam 2200301za 4500 |
|---|
| 001 | 9.847949 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153547 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171128s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660240350|z9780660240367 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-183/2017E-PDF |
|---|
| 110 | 2 |aNational Research Council Canada. |
|---|
| 245 | 10|aVaccine formulation and immunomodulation |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
|---|
| 300 | |a[1] p. : |bcol. ill. |
|---|
| 500 | |aIssued also in French under title: Formulation de vaccins et immunomodulation. |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"January 2017." |
|---|
| 520 | |a“The NRC has been developing vaccines for over 35 years and has recently expanded its activities in immunotherapy. We work with Canadian and international partners to design and test new vaccines and immunotherapeutics.” |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aVaccines |
|---|
| 693 | 4|aImmunological adjuvants |
|---|
| 775 | 08|tFormulation de vaccins et immunomodulation |w(CaOODSP)9.847954 |
|---|
| 776 | 0#|tVaccine formulation and immunomodulation |w(CaOODSP)9.847952 |
|---|
| 856 | 40|qPDF|s63 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-183-2017-eng.pdf |
|---|